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Abstract
Antamanide is a cyclic decapeptide derived from the fungus Amanita phalloides. Here we show that antamanide inhibits the
mitochondrial permeability transition pore, a central effector of cell death induction, by targeting the pore regulator
cyclophilin D. Indeed, (i) permeability transition pore inhibition by antamanide is not additive with the cyclophilin D-binding
drug cyclosporin A, (ii) the inhibitory action of antamanide on the pore requires phosphate, as previously shown for
cyclosporin A; (iii) antamanide is ineffective in mitochondria or cells derived from cyclophilin D null animals, and (iv)
abolishes CyP-D peptidyl-prolyl cis-trans isomerase activity. Permeability transition pore inhibition by antamanide needs two
critical residues in the peptide ring, Phe6 and Phe9, and is additive with ubiquinone 0, which acts on the pore in a
cyclophilin D-independent fashion. Antamanide also abrogates mitochondrial depolarization and the ensuing cell death
caused by two well-characterized pore inducers, clotrimazole and a hexokinase II N-terminal peptide. Our findings have
implications for the comprehension of cyclophilin D activity on the permeability transition pore and for the development of
novel pore-targeting drugs exploitable as cell death inhibitors.
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Introduction
Antamanide (AA) is a monocyclic, homodetic decapeptide
isolated from the poisonous mushroom Amanita phalloides [1]. AA
has been extensively studied for its strong antidote activity against
phallotoxins and amatoxins, which are extremely toxic peptides
isolated from the same fungus [2]. It was also reported that AA
inhibits tumor cell growth in vitro [3], displays an antitumor action
in an animal model [4], and attenuates IL-2-induced multisystem
organ edema [5]. Little is known about the biochemical
mechanisms underlying these diverse bioactivities. To explain its
antitoxic activity, it was proposed that AA competitively
antagonizes a hepatocyte membrane transporter for the phallo-
toxin phalloidin and for the amatoxin alpha-amanitin [6,7]. This
transporter was later identified as a member of the organic anion-
transporting polypeptide family [8,9]. Notably, cell uptake of
phalloidin was also inhibited by the immunosuppressive drugs
rapamycin, FK506 or cyclosporin A (CsA) [8], and AA itself acts
as an immunosuppressant [10,11]. These observations strongly
suggest that AA could interact with the immunophilins FK506BP
or cyclophilin (CyP) A, which are the protein targets of
rapamycin/FK506 and CsA, respectively [12,13].
CyP-A is a component of the CyP protein family, whose
members display peptidyl-prolyl cis-trans isomerase activity [14]
and are characterized by a high degree of sequence conservation
and by a differential subcellular distribution [15]. We therefore
reasoned that if the AA target was the cytosolic CyP-A, the drug
could also act on other members of this protein family. Indeed,
such a pleiotropic effect is well-characterized for CsA, as CsA also
targets the mitochondria-restricted CyP-D [16–18]. CyP-D
displays an important role in the cell response to a variety of
noxious stimuli, as it modulates a channel located in the inner
mitochondrial membrane, the permeability transition pore (PTP)
[19,20], whose prolonged opening irreversibly commits cells to
death [21]. PTP dysregulation is emerging as a common feature in
a variety of pathologies endowed with either an excess of cell
death, such as neurodegenerative disease or muscular dystrophies,
or with an aberrant hyperactivation of survival pathways, as in
cancer [21,22]. CsA inhibits PTP opening through binding to
CyP-D [21]. Therefore, it constitutes an interesting molecule for
the treatment of degenerative diseases [23,24]. Nonetheless, due to
its immunosuppressant activity, to its side effects [25] and to its
inability to pass the blood-brain barrier [24], CsA analogues with a
higher selectivity for CyP-D are under intense scrutiny [23,26–29].
Here we demonstrate that, similar to CsA, AA targets CyP-D
leading to PTP inhibition and to cell protection from insults that
cause pore opening. AA could be exploited as a lead compound for
a new class of PTP-inhibiting drugs.
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AA inhibits the PTP in isolated mitochondria
AA is the cyclodecapeptide c(Val-Pro-Pro-Ala-Phe-Phe-Pro-
Pro-Phe-Phe) (Figure 1A). To evaluate its effect on the PTP, we
performed Ca
2+ retention capacity (CRC) assays on isolated
mouse liver mitochondria (MLM). Notably, when mitochondria
were incubated in a phosphate-containing medium, AA inhibited
pore opening, similar to the PTP inhibitors CsA or Ubiquinone 0
(Ub0; Figure 1B,C). PTP inhibition by AA was not additive with
that of CsA, whose molecular target is CyP-D, while AA did
increase inhibition by Ub0, which is independent of CyP-D
(Figure 1C). We had shown that the effect of CsA, but not of Ub0,
is abolished by substituting phosphate with arsenate [30].
Likewise, AA inhibition of the PTP was abrogated in the presence
of arsenate (Figure 1D). To dissect AA potency as a PTP inhibitor
and the residues involved in its activity, we performed a
concentration-response CRC experiment on MLM treated with
AA or with a panel of derivatives (Figure 2A). We found that the
effect of AA reached a plateau at a concentration of about 20 mM,
and that changing amino acids in position 6 or 9 completely
abolished pore inhibition (Figure 2B,C).
Figure 1. Effect of AA on PTP opening in isolated mouse liver mitochondria. A, chemical structure of AA. B, D, Ca
2+ retention capacity (CRC)
either in phosphate (Pi) buffer (B) or in arsenate (Asi) buffer (D). Calcium Green-5N fluorescence is reported as arbitrary units on the y axis. As the
probe does not permeate mitochondria, Ca
2+ uptake into the organelles is displayed as a rapid decrease of the fluorescence spike after
administration of every Ca
2+ pulse (10 mM each). AA (red trace, 8 mM) or CsA (0.8 mM) act as pore inhibitors only in Pi buffer (B), as they increase the
threshold Ca
2+ concentration required to trigger the permeability transition, i.e. the number of spikes before a sudden and marked fluorescence
increase occurs. Ub0 (25 mM) inhibits the pore also in Asi buffer, albeit to a lesser extent. C, inset of D, quantification of the effect of PTP inhibitors is
displayed as the ratio between the CRC detected in the presence (CRC) and absence (CRC0) of the compound. Results are mean6SD of at least 4
experiments. In C and D, we analyzed whether each pharmacological treatment increased mitochondrial Ca
2+ uptake when compared to control
conditions (Ca
2+ uptake in the absence of the drug), and found a significant difference (Student’s t test analysis; *: p,0.01) between the CRC of
mitochondria treated with either AA (at various concentrations), or CsA, or Ub0 and the CRC of untreated mitochondria, indicating that each of these
treatments inhibits the PTP. In C, significant differences were also observed between the CRC of mitochondria treated with either Ub0/AA or Ub0/CsA
and with Ub0 by itself (Student’s t test analysis; #:p ,0.01), indicating that the inhibitory effect of both AA and CsA on the PTP is additive with that of
Ub0.
doi:10.1371/journal.pone.0016280.g001
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The above data strongly suggested that AA could target
mitochondrial CyP-D. To formally establish whether the interac-
tion between AA and CyP-D determines PTP inhibition, we
purified mitochondria from either wild-type or Ppif
2/2 (CyP-D
null) mouse fibroblasts [Figure 3A and 27]. First, we measured
oxygen consumption, and we found that this is unaffected by AA
both in wild-type and in CyP-D knock-out cells, as well as in
mouse liver mitochondria (Figure 3A and data not shown). We
then assessed CRC modulation. Consistent with results obtained
on MLM, we found that AA inhibited the pore in mitochondria
from wild-type fibroblasts, and that this effect was not enhanced by
CsA (Figure 3B). Remarkably, AA was totally ineffective on
mitochondria from CyP-D knock-out fibroblasts (Figure 3B). We
confirmed these observations by CRC whole-cell experiments, i.e.
by measuring mitochondrial Ca
2+ retention capacity on digito-
nized cells (Figure 4A–C). We then repeated CRC experiments on
human cervix adenocarcinoma HeLa cells, to address the issue of
cell- and species-specificity. Our results confirmed those obtained
in the mouse model, as AA inhibited the pore also in mitochondria
isolated from HeLa cells, and the effect of AA did not add to that
of CsA (Figure 5A). In addition, CyP-D was directly targeted by
AA, as AA abrogated the peptidyl-prolyl cis-trans isomerase activity
of purified CyP-D (Figure 4D).
AA inhibits PTP-induced cell death
The potential pharmacological use of AA as a PTP modulator
required to address whether the compound is active in whole cells.
To this aim, we exploited the sensitivity of HeLa cells to PTP
opening and to the ensuing apoptosis following hexokinase II
(HKII) detachment from mitochondria with the drug clotrimazole
(CTM) or with a HKII-displacing peptide (TAT-HK; [27]). We
found that the marked mitochondrial depolarization induced by
CTM or TAT-HK was similarly reverted by CsA or AA
(Figure 5B,C). Moreover, HKII displacement from mitochondria
with TAT-HK prompted a fast and dramatic cell death, mainly
necrosis, as indicated by the low cell staining with the apoptosis
marker Annexin V in the presence of a massive propidium iodide
signal (Figure 6A,B). Either CsA or AA virtually abolished the
necrotic response, whereas a small fraction of cells undergoing
apoptosis was still detectable (Figure 6A,B), in line with the
observation that modulating the intensity of the stress stimulus can
switch the mode of cell death between apoptosis and necrosis [31].
A similar degree of cell death was observed when cells were treated
with clotrimazole, and again either CsA or AA inhibited the
process (data not shown).
Discussion
The identification of PTP targeting drugs is a highly desirable
result, as the PTP is involved in a wide range of diseases. By the
use of CsA or of CyP-D knock-out animals it was established that
dysregulated PTP induction is implicated in various forms of brain
damage [32,33] and neurodegenerative diseases [34], in muscular
dystrophies caused by collagen VI deficiency [23], in hepatotox-
icity, in ischemic injury of kidney, brain and heart and in cardiac
ischemia/reperfusion damage [21,22].
Figure 2. Phe residues in position 6 and 9 of AA are required for PTP inhibition. A, amino acid sequence of AA derivatives tested on the
PTP. Amino acid changes are outlined in red. B, Ratio between the CRC detected in the presence (CRC) and absence (CRC0) of increasing
concentrations of AA and derivatives. The CRC/CRC0 ratio is calculated as in Figure 1. Results are mean6SD of at least 4 experiments. C,
Representative experiment showing the lack of effect on Ca
2+ retention capacity (CRC) of the octa-Gly
9 AA derivative. Traces are reported as in Fig.
1B.
doi:10.1371/journal.pone.0016280.g002
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CyP protein family, composed by ubiquitous and extremely
conserved proteins located in different subcellular compartments
[12,35]. A first generation of CyP inhibitors (e.g. Debio-025 or
NIM811) has overcome the problems connected to the immuno-
suppressant activity of CsA, caused by the formation of a CyP-A/
CsA complex in the cytosol that inhibits lymphocyte activation,
blocking the NF-AT transcription factor [36]. These molecules
display promising clinical effects, as shown by their use in the
treatment of some viral infections. Indeed, the chaperone activity
of CyPs probably controls the correct folding of viral proteins.
CyP-A interacts both with the HIV Gag protein and with the
HCV NS5B polymerase, and both CsA and non-immunosup-
pressant CsA derivatives prevent HCV/HIV replication and are
in phase I/II clinical trials [35]. In a different pathological setting,
it is noteworthy that Debio-025 normalizes mitochondrial function
and apoptotic rate on muscle samples derived from patients
affected by Ullrich muscular dystrophy [37] and in a mouse model
of the disease [38]. Nonetheless, these results are hampered by
severe side effects of CsA derivatives, including nephrotoxicity,
neurotoxicity, and hepatotoxicity [36], and by their poor
permeability to the blood brain barrier [39]. Thus, a second
generation of CyP inhibitors should demonstrate increased efficacy
and improved safety profiles, and AA could be a lead compound in
the search for new therapeutic molecules.
To the aim of selecting these more efficacious drugs, a fine
comprehension of the interaction with their molecular targets is
needed. The CsA-binding pocket of CyPs is formed by an
extended groove where the isomerase active site is located. CsA
half-inserts in the cavity, and a high binding affinity to CyPs
requires the sum of multiple interactions: six CsA amino acids
(residues 1–2 and 8–11) establish hydrogen bonds and hydropho-
bic contacts with 15 CyP amino acids. Residues 3–7 of CsA are
exposed to the outside of the CyP-CsA complex and are prone to
interact with other molecules [39]. In the case of AA, it was
suggested that Phe6 and Phe9 are located in the region primarily
affected by conformational variations [3], and a NMR study shows
a high degree of flexibility when any of the two Phe residues is
substituted with Gly [40]. We have found that substitutions in
Phe6 or Phe9 abolish every effect on the PTP (see Figure 2B).
Similarly, changes in these residues abrogate cell growth inhibition
and cytotoxicity elicited by AA in tumour cell models [3,40].
It must be highlighted that the biological activities of AA are
possibly wider than the presently reported PTP inhibition. Indeed,
both AA and CsA inhibit the PTP (present results), block cell
uptake of the phallotoxin phalloidin ([8] and our unpublished
data) and act as immunosuppressants [10,11]. It is therefore highly
probable that, similar to CsA, AA targets multiple cell CyPs. The
CyP chaperone activity, i.e. the isomerization to the cis form of the
peptidyl bonds preceding each proline [14], is involved in folding
and association processes required for proteins to perform their
functions [39]. Here we show that, similar to CsA, AA abrogates
the peptidyl-prolyl cis-trans isomerase activity of CyP-D. This
observation strongly suggests that the enzymatic inhibition of CyP-
D is the molecular mechanism responsible for PTP inhibition.
Thus, AA could have diverse biological effects, as CyPs modulate a
variety of cell processes, including gene transcription, proliferation,
survival, chemotaxis and motility, targeting molecules as diverse as
the transcription factor NF-AT, MAP kinase upstream regulators
[36], the membrane receptors CD147 and CXCR4 [39,41,42],
Figure 3. Effect of AA on respiration and PTP opening in mitochondria of wild-type or CyP-D knock-out mouse fibroblasts. A, upper
part: Western blot analysis assessing CyP-D expression in fibroblasts obtained from either wild-type or CyP-D knock-out mice; HKII was utilized to
verify protein load; lower part: representative experiment showing oxygen consumption as assessed by polarography (see Methods) in mitochondria
isolated from wild-type fibroblasts in the absence (a) or presence (b) of 8 mM AA. Experiments were started by adding 0.6 mg of mitochondria (Mito),
followed by 100 mM ADP and 50 mM 2,4-dinitrophenol (DNP) (arrows). Each experiment was repeated at least three times. Oxygen consumption is
reported as percentage of initial value on the y axis. B, bar graphs report the ratio between the CRC detected in the presence (CRC) and absence
(CRC0) of increasing concentrations of AA, in mitochondria from either wild-type fibroblasts (left) or CyP-D knock-out fibroblasts (right). PTP inhibition
by AA and CsA is not additive. Results are mean6SD of at least 4 experiments. We analyzed whether each pharmacological treatment increased
mitochondrial Ca
2+ uptake when compared to control conditions (Ca
2+ uptake in the absence of the drug), and found a significant difference
(Student’s t test analysis; *: p,0.01) between the CRC of mitochondria treated with either AA (at various concentrations), or CsA, and the CRC of
untreated mitochondria, indicating that each of these treatments inhibits the PTP.
doi:10.1371/journal.pone.0016280.g003
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highlighted that the impact of AA on cellular routines could be
context-dependent, as different cell types utilize CyPs for a variety
of processes under diverse conditions. An example of this
complexity is provided by carcinogenesis. PTP inhibition contrib-
utes to the apoptosis resistance that characterizes neoplastic
transformation [22,46]. Therefore, a further PTP inhibition
provided by AA should favor tumor growth. Accordingly, it was
observed that CsA can enhance the progression of certain
malignancies [47]. However, the issue of the CyP role in
tumorigenesis is complicated by the observation that CyP-A is
upregulated in a variety of tumor models, where it is involved in
cancer cell survival, resistance to chemotherapeutics and metas-
tasis [41,48,49], and that CsA treatment induces tumor necrosis
and abrogates metastasis formation [45]. Moreover, CsA inhibits
multidrug resistance proteins that are responsible for tumor
chemoresistance [50].
It is known that AA abrogates the toxic effects of the phallotoxin
phalloidin [8,9]. We confirmed that AA inhibits membrane
permeabilization by phalloidin (data not shown). However, we
could not detect any effect of phalloidin either on mitochondrial
Ca
2+ retention capacity, or on mitochondrial potential (Figure S1).
Therefore, phalloidin is inactive on the PTP, suggesting that AA
counteracts its toxicity with a mechanism independent of pore
inhibition, possibly antagonizing cell uptake of phallotoxins [8,9].
In summary, we provide evidence that AA inhibits the
mitochondrial PTP by targeting the peptidyl-prolyl cis-trans
isomerase CyP-D, thus abrogating cell death caused by PTP
inducers. AA could be exploited as a lead compound for the design
of new CyP inhibitors, with implications for the pharmacological
treatment of diverse pathological conditions.
Materials and Methods
Chemicals and cells
FITC-conjugated Annexin-V was from Boehringer Mannheim
(Indianapolis, IN); Calcium Green-5N and tetramethylrhodamine
methyl ester (TMRM) were from Molecular Probes (Eugene, OR);
dinitrophenol was from Merck (Darmstadt, Germany); digitonin
was from Calbiochem (San Diego, CA); all other chemicals were
from Sigma (St. Louis, MO). Diaphragm adult fibroblasts were
obtained by SV40 immortalization of primary cells from wild-type
and Ppif
2/2 mice [27]; apoptosis inducers were added to
exponentially growing cells in the absence of serum. Each
experiment was repeated at least three times.
Peptide synthesis
AA and four derivatives, Tyr9-AA, Gly9-AA, Gly6-AA, and
octa-Gly9-AA were synthesized as reported elsewhere [3]. Briefly,
the synthetic route was based on the preparation of three different
fragments corresponding to the sequences 1–4 (containing ab initio
a C-terminal tert-butyloxycarbonyl-protected hydrazide moiety),
5–6 and 7–10. These fragments were subsequently assembled by
the azide method following the Rudinger procedure obtaining the
linear 5-4 sequence of AA. The same method was used for the
cyclization reaction exploiting the possibility to separate the
activation from the condensation which was carried out at
concentration not exceeding 10
23 M in the presence of an
Figure 4. Effect of AA on PTP opening in wild-type or CyP-D knock-out mouse fibroblasts and on CyP-D isomerase activity. A, B, PTP
opening of digitonized wild-type (A) or CyP-D knock-out (B) fibroblasts was measured with the whole-cell CRC assay. Experiments were started by the
addition of digitonized cells (not shown) followed by pulses of Ca
2+ (5 mM each) and are plotted as in Figure 1B. The use of AA is shown with a red
trace. Alamethicin (Alm, 1 mM) was added at the end of each measurement to fully release Ca
2+ from intracellular stores. C, the CRC/CRC0 ratio
calculated as in Figure 1C indicates that both AA and CsA display an inhibitory effect on the PTP in wild-type, but not in CyP-D knock-out fibroblasts.
Results are mean6SD of at least 4 experiments. We analyzed whether each pharmacological treatment increased mitochondrial Ca
2+ uptake when
compared to control conditions (Ca
2+ uptake in the absence of the drug), and found a significant difference (Student’s t test analysis; *: p,0.01)
between the CRC of mitochondria treated with either AA or CsA, and the CRC of untreated mitochondria, indicating that each of these treatments
inhibits the PTP in wild-type fibroblasts. D, isomerase activity assay (see Materials and Methods): after addition of the substrate peptide N-succinyl-
Ala-Ala-cis-trans-Pro-Phe-p-nitroanilide (arrow), chimotrypsin cleaves the trans-isomeric form, causing a rise in absorbance. AA (8 mM) and CsA (8 mM)
act as inhibitors of the enzymatic activity of CyP-D.
doi:10.1371/journal.pone.0016280.g004
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16280Figure 5. Effect of AA on mitochondrial potential of HeLa cells. A, bar graphs report the ratio between the CRC detected in the presence
(CRC) and absence (CRC0) of increasing concentrations of AA in mitochondria from HeLa cells. PTP inhibition by AA and CsA is not additive. Results
are mean6SD of at least 4 experiments. We analyzed whether, in mitochondria from HeLa cells, each pharmacological treatment increased Ca
2+
uptake when compared to control conditions (Ca
2+ uptake in the absence of the drug), and found a significant difference (Student’s t test analysis; *:
p,0.01) between the CRC of mitochondria treated with either AA (at various concentrations), or CsA, and the CRC of untreated mitochondria,
indicating that each of these treatments inhibits the PTP. B,C cytofluorimetric analysis of mitochondrial depolarization. HeLa cells were incubated
with the TMRM probe and treated for 1 hour with the reported concentrations of either clotrimazole (CTM) or TAT-HK peptide. An unrelated TAT-
linked peptide (TAT-Ctr) is used as a negative control. Before the addition of either CTM or TAT-peptides, cells were preincubated for 30 minutes with
CsA or AA, or with the CsA analogue cyclosporin H (in the dubbed Ctr conditions), to exclude for changes in TMRM signal unrelated to mitochondrial
potential (see Methods). Bar graphs in B display the percentage of cells with depolarized mitochondria (mean6SD, n=4). We analyzed whether each
pharmacological treatment increased the percentage of HeLa cells with depolarized mitochondria when compared to control conditions (i.e.,
percentage of cells with depolarized mitochondria in the absence of the drug), and found a significant difference (Student’s t test analysis; #:p ,0.01)
between cells treated with either CTM or TAT-HK, and untreated cells, indicating that each of these compounds damages mitochondria. A similar pair
wise comparison allowed to establish that pretreatment with either AA or CsA significantly decreased the percentage of cells with mitochondria
depolarized by CTM (Student’s t test analysis; *: p,0.01) or by TAT-HK (Student’s t test analysis; **: p,0.01). Histograms in C report a representative
experiment, where cells with polarized and depolarized mitochondria are indicated in red and grey, respectively.
doi:10.1371/journal.pone.0016280.g005
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Sephadex LH-20 (GE Healthcare Bio-Sciences, Uppsala, Sweden)
column equilibrated and eluted with methanol-water (8:2 v/v).
Molecular masses of the peptides were confirmed by ESI-MS on a
Mariner (PerSeptive Biosystem, Foster City, CA) mass spectrom-
eter. The purity of the peptides, assessed by analytical reverse
phase HPLC, was higher than 95%. The amino acid compositions
of the peptide acid hydrolysates (6 M HCl, 22 h at 110uC in sealed
evacuated vials) were determined with a 3A30 (Carlo Erba, Milan,
Italy) amino acid analyzer. Peptides MIASHLLAYFFTELNbA-
GYGRKKRRQRRRG (TAT-HK) and GYGRKKRRQRRRG-
bA-EEEAKNAAAKLAVEILNKEKK (TAT-Ctr) were synthe-
sized as described [27] by a solid phase method using an
automatized peptide synthesizer (model 431-A, Applied Biosys-
tems, Foster City, CA) and the fluoren-9-ylmethoxycarbonyl
(Fmoc) strategy. HMPA PEGA resin (Novabiochem, Bad Soden,
Germany) was used as solid support. Peptides were cleaved from
the resins with a TFA/H20/thioanisole/ethanedithiol/phenol
mixture. Crude peptides were purified by a preparative reverse
phase HPLC. Molecular masses of the peptides were confirmed by
mass spectroscopy with direct infusion on a Micromass ZMD-
4000 Mass Spectrometer (Waters-Micromass). The purity of the
peptides was about 95% as evaluated by analytical reverse phase
HPLC.
Isolation of mitochondria
Mitochondria were isolated either from livers of C57BL/6 mice
through sequential centrifugations, or from cells, as described [27].
To obtain mitochondria, cells were disrupted with a glass-Teflon
potter in a buffer composed by 250 mM sucrose, 10 mM Tris-
HCl, 0.1 mM EGTA-Tris, pH 7.4. Nuclei and plasma membrane
fractions were separated by a first mild centrifugation (7006 g,
10 min), and mitochondria were then spinned down at a higher
speed (70006 g, 10 min). All procedures were carried out at 0–
4uC.
Measurement of mitochondrial Ca
2+ retention capacity
The Ca
2+ retention capacity (CRC) assay was used to assess
PTP opening following trains of Ca
2+ pulses and measured
fluorimetrically at 25uC in the presence of the Ca
2+ indicator
Calcium Green-5N (1 mM; lexc: 505 nm; lem: 535 nm; Molecular
Probes). Experiments were performed either on isolated mito-
chondria or on whole cells [27]. Cells were washed in an isotonic
buffer (130 mM KCl, 1 mM Pi-Tris, 10 mM Tris/Mops, and
0.1 mM EGTA/Tris, pH 7.4), and then permeabilized with
150 mM digitonin (15 min, 4uC), increasing EGTA to 1 mM.
Digitonin was then eliminated and the number of cells carefully
assessed before starting each experiment. Permeabilized cells or
isolated mitochondria were placed in low (10 mM) EGTA in the
presence of 2 mM rotenone/5 mM succinate, 10 mM cytochrome
c, and Calcium Green-5N, which does not permeate mitochon-
dria. Cells or mitochondria were then exposed to Ca
2+ spikes, and
fluorescence drops were used to assess mitochondrial Ca
2+ uptake.
PTP opening was detected as a fluorescence increase. Calcium
Green-5N fluorescence was measured either with a fluorescence
spectrometer LS50B (Perkin Elmer, Waltham, MA) or with a
Fluoroskan Ascent FL fluorimeter (Thermo Electron Corporation,
Waltham, MA).
Western Immunoblot Analysis
Cell extracts were prepared at 4uC in 140 mM NaCl, 20 mM
Tris?HCl (pH 7.4), 5 mM EDTA, 10% glycerol, and 1% Triton
Figure 6. Effect of AA on HeLa cell viability. A, cytofluorimetric analysis of cell death induction in HeLa cells treated for 1 hour with TAT-HK.
Where indicated, cells were preincubated for 30 minutes with CsA or AA. TAT-Ctr was used as a negative control. Cells were double stained with
Annexin V-FITC and propidium iodide (PI), to respectively evaluate apoptosis induction as phosphatidylserine exposure on the cell surface (increased
Annexin V-FITC staining) and cell death as plasma membrane permeabilization (increased PI staining). We considered Annexin V
+ as early/
intermediate apoptotic cells; PI
+ as necrotic cells; double stained as late apoptotic cells. Bar graphs display the percentage of each cell population
(mean6SD, n=4; double positive cells are added to both bars). The number of PI+ cells was significantly increased by TAT-HK treatment (Student’s t
test analysis; #:p ,0.01 when comparing untreated and TAT-HK treated HeLa cells). Moreover, HeLa cell pretreatment with either AA or CsA
significantly protected from TAT-HK induced death (Student’s t test analysis; *: p,0.01 when comparing TAT-HK treated HeLa cells pretreated or not
with either AA or CsA). B, histograms reporting a representative experiment, where viable cells are indicated in red, PI
+- and Annexin V
+-cells are
indicated in grey and green, respectively.
doi:10.1371/journal.pone.0016280.g006
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(Sigma). Samples were then denatured, separated in reducing
conditions on SDS-polyacrylamide gels and transferred onto
Hybond-C Extra membranes (Amersham, Little Chalfont, UK).
Primary antibodies were incubated 16 hours at 4uC, and
horseradish peroxidase-conjugated secondary antibodies were
added for 1 hour. Proteins were visualized by enhanced
chemiluminescence (Millipore, Billerica, MA).
Mitochondrial respiration assay
Mitochondrial oxygen consumption was measured polaro-
graphically at 25uC with a Clark oxygen electrode (Yellow Springs
Instruments, OH, USA). Mitochondria (0.6 mg per experimental
point) were incubated in a solution of 130 mM KCl, 10 mM Tris-
Mops, 1 mM Pi-Tris, 20 mM EGTA-Tris and 2 mM rotenone/
5 mM succinate to assay basal respiration (state 4). ADP (200 mM)
was subsequently added to measure state 3 respiration, followed by
the uncoupling agent dinitrophenol (100 mM) to assess the
maximal respiration rate.
Flow cytometry analysis of mitochondrial depolarization
and cell death induction
Flow cytometry recordings were performed as described
[31,51,52]. Briefly, at the end of the incubation, cells were
resuspended in 135 mM NaCl, 10 mM HEPES, 5 mM CaCl2 and
incubated at 37uC in either TMRM (10 nM) to detect
mitochondrial depolarization (reduced TMRM staining), or in
FITC-conjugated Annexin-V and propidium iodide (PI, 1 mg/ml),
to detect phosphatidylserine exposure on the cell surface (increased
FITC-conjugated Annexin-V staining) and loss of plasma
membrane integrity (PI permeability and staining). When TMRM
was used to detect mitochondrial membrane potential, in each
experiment one sample was treated with the protonophore FCCP
(4 mM) as a positive control (full mitochondrial depolarization).
Moreover, as TMRM can be pumped out of cells by multidrug
resistance systems, and CsA is a multidrug resistance inhibitor, the
CsA analogue cyclosporin H, which is inactive on the PTP, was
used to block multidrug resistance in the absence of CsA [37].
Samples were analyzed on a FACSCanto II flow cytometer
(Becton Dickinson, San Diego, CA, USA). Data acquisition and
analysis were performed using FACSDiva software.
PPIase Activity of CyP-D
The PPIase activity was assessed on recombinant CyP-D (10 ng
per experimental point). The CyP-D cDNA was cloned in a
pcDNA3 vector (Invitrogen, Carlsbad, CA) with a FLAG tag
added at its 39 end [22], and then purified by immunoprecipitation
with a FLAG displacing peptide (Sigma). The enzymatic assay was
performed following through a spectrophotometric analysis the
rate of hydrolysis of N-succinyl-Ala-Ala-cis-trans-Pro-Phe-p-nitroa-
nilide by chymotrypsin, as previously reported [53]. Chymotrypsin
hydrolyzes only the trans form of the peptide, which is revealed as a
rise in absorbance at 410 nM. The concentration of of the cis form
is maximized by using a peptide stock dissolved in trifluoroethanol
containing 470 mm LiCl, and its hydrolysis is limited by the rate of
cis-trans isomerization.
Supporting Information
Figure S1 Effect of phalloidin (Ph) on mitochondria and
cells. A, ratio between the CRC detected in the presence (CRC)
and absence (CRC0) of Ph (50 mg/ml) in MLM. The effects of CsA
(0.8 mM) and AA (8 mM) are reported as positive controls. Results
are mean6SD of 3 experiments. B, cytofluorimetric analysis of
mitochondrial membrane potential after a 1 hour incubation with
Ph (50 mg/ml). Treatment with the proton uncoupler FCCP
(4 mM) is shown as a positive control of mitochondrial depolar-
ization. Graphs report a representative experiments, where HeLa
cells with polarized and depolarized mitochondria are indicated in
red and grey, respectively. D is the percentage of cells with
depolarized mitochondria.
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